Milnacipran

When ATH:
N06AA24

Pharmacological action.
Antidepressant.

Application.

Depressions.

Contraindications.

Hypersensitivity, benign prostatic hyperplasia glands, simultaneous reception of MAO inhibitors type A and B, selective inhibitors of reverse neuronal serotonin reuptake, adrenaline, noradrenaline, klonidina, digoksina, moclobemide, pregnancy, lactation, childhood and adolescence (to 15 years).

Pregnancy and breast-feeding.

Contraindicated in pregnancy. At the time of treatment should stop breastfeeding.

Side effects.

Dizziness, Sweating, alarm, tides, tremor, heartbeat, dry mouth, nausea, vomiting, constipation, urinary retention, increase in transaminases.

Cooperation.

Incompatible with MAO inhibitors and serotonergic agents (such as tryptophan or fenfluramine). Reduces hypotensive effect of clonidine and its derivatives. It changes the level of lithium in the blood. Epinephrine and norepinephrine provoke the development of hypertensive crisis and arrhythmia. Digoxin (especially with parenteral use) increases hemodynamic disorder.

Dosing and Administration.

Inside (preferably during meals), by 50 mg 2 once a day, for several months (the duration of treatment is determined individually).

Precautions.

Patients with renal impairment dose reduction is recommended based on creatinine clearance. Between MAO inhibitors, and requires a two-week range of milnacipran. During therapy, the use of alcohol is not permitted. Should not be used during the drivers of vehicles and people, skills relate to the high concentration of attention.

Cooperation